Crohn’s Disease

“SSIs offer an innovative, novel approach to improving care within the context of trusted, credible scientific studies.”

~ Dr. Simon Sutcliffe, Chief Medical Officer, Qu Biologics

NOW Enrolling: RESTORE Crohn’s disease trial – Stage 1

Qu Biologics is now recruiting Canadian residents to participate in the first stage of a Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease. Learn more and fill out the pre-screening questionnaire at www.restoretrial.ca

The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the induction of clinical and endoscopic response and remission. QBECO SSI is intended to restore innate immune function and achieve sustained remission off all medications. In addition, this study will help to determine whether improvement in endoscopic healing is seen after 16 weeks or after 26 weeks of treatment.

For more information, check out our webinars about the trial.

See the results from our Phase 2 68-patient randomized, placebo-controlled clinical trial for the treatment of Crohn’s disease here.

Do you have Crohn’s Disease?

Qu Biologics has developed QBECO SSI, an investigational treatment designed to restore normal immune function.

Qu Biologics’ proprietary Site Specific Immunomodulators (SSIs) are investigational treatments designed to restore normal immune function in the targeted tissue to reverse the chronic inflammation underlying many chronic illnesses, including Crohn’s disease. E. coli is a bacterium that is a common cause of gastrointestinal infection. QBECO SSI is derived from components of inactivated E. coli and aims to simulate infection without causing it and, in so doing, stimulates a targeted innate immune response in the gastrointestinal tract to clear the chronic infection and dysbiosis that may underlie Crohn’s disease. Read more about QBECO SSI treatment for Crohn’s disease and how SSIs work.

Colon

 

Qu Biologics’ clinical trial in Crohn’s Disease

Qu Biologics has completed a Phase 2 68-patient randomized, placebo-controlled clinical trial for the treatment of Crohn’s disease.  A summary of the results from this Health Canada-approved trial can be found here.

Plans are underway for a follow-on, multi-center clinical trial in Crohn’s disease, to start in 2018. If you are interested in participating in our next clinical trial of QBECO SSI for the treatment of Crohn’s disease, you may sign up here.

Join our IBD Community Advisory Panel

If you are someone living with inflammatory bowel disease or are a caregiver, we’d like to hear from you! You could make a difference in how our clinical trials are designed. Learn more about joining our IBD Community Advisory Panel.

For more information on our clinical program in Crohn’s disease visit www.quibd.com.

Past events:


Past events: